TCGA-A7-A0D9-01A-31R-A056-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 38
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.320
- HEDGEHOG_SIGNALING+0.300
- PROTEIN_SECRETION+0.270
- UNFOLDED_PROTEIN_RESPONSE+0.170
- UV_RESPONSE_DN+0.140
- NOTCH_SIGNALING+0.120
- ADIPOGENESIS+0.100
- PANCREAS_BETA_CELLS+0.070
- ANGIOGENESIS+0.060
- ESTROGEN_RESPONSE_EARLY+0.050
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.610
- INTERFERON_GAMMA_RESPONSE-0.590
- ALLOGRAFT_REJECTION-0.580
- IL6_JAK_STAT3_SIGNALING-0.490
- E2F_TARGETS-0.460
- G2M_CHECKPOINT-0.420
- INFLAMMATORY_RESPONSE-0.420
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.390
- TNFA_SIGNALING_VIA_NFKB-0.390
- COMPLEMENT-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8392885 | — | cohortA3 | 0.888 |
| 2 | SRR8518202 | — | A | 0.850 |
| 3 | 20030017.LumA | — | B | 0.848 |
| 4 | MBCProject_0063_T1_RNA | — | C | 0.844 |
| 5 | TCGA-A2-A1FV-01A-11R-A13Q-07 | — | B | 0.843 |
| 6 | sclcCHTN02019_S70.txt | — | cohortSC | 0.839 |
| 7 | TCGA-B6-A0I8-01A-11R-A034-07 | — | B | 0.838 |
| 8 | C3N-02973 | — | cohortA1 | 0.833 |
| 9 | SRR25617895 | — | B | 0.832 |
| 10 | SRR8613752 | — | A | 0.828 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.320 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.300 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.270 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.170 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.140 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.120 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.070 | Cobimetinib | — uncovered |
| ANGIOGENESIS | 0.060 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.050 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.040 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.020 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.020 | Inavolisib | — uncovered |